MGMT and gliosarcoma: In addition, the combination of nedisertib and radiotherapy is being evaluated in phase I trials with MGMT unmethylated glioblastoma or gliosarcoma (NCT04555577), advanced head and neck cancer (NCT04533750) and phase I/II trials in patients with pancreatic cancer (NCT04172532).